NeuroMetrix (NASDAQ:NURO) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report released on Friday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NASDAQ:NURO opened at $3.71 on Friday. The stock has a fifty day moving average price of $4.04 and a 200-day moving average price of $3.71. The company has a market cap of $7.46 million, a price-to-earnings ratio of -0.59 and a beta of 2.16. NeuroMetrix has a fifty-two week low of $2.70 and a fifty-two week high of $8.30.

NeuroMetrix (NASDAQ:NURO) last released its earnings results on Wednesday, May 15th. The medical device company reported ($1.67) earnings per share for the quarter. The company had revenue of $1.09 million for the quarter. NeuroMetrix had a negative net margin of 151.51% and a negative return on equity of 39.85%.

Institutional Trading of NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. Cerity Partners LLC acquired a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned about 2.80% of NeuroMetrix as of its most recent SEC filing. 19.40% of the stock is currently owned by hedge funds and other institutional investors.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.